🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Hui Gan

La Trobe University

ORCID: 0000-0001-7319-8546

Also affiliated with Austin Hospital, Chengdu University of Technology, Xinjiang Institute of Ecology and Geography, Olivia Newton-John Cancer Wellness & Research Centre, Children's Hospital of Chongqing Medical University, Austin Health, Olivia Newton-John Cancer Research Institute, Southwest Minzu University, Chongqing Medical University, Northwest A&F University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6532395
Top 100%
0DataRank
Top 100%0 citations

Nathan Standifer, Jörg Dietrich, Jennifer Clarke, Gavin P. Dunn, Michael Lim +21 more

Papers

Driven by 11 papers — median percentile 0. Top paper: “Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin”.

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

Neuro-Oncology Advances(2021)10.1093/noajnl/vdab102
N/A
0DataRank · unranked
11 citations

Sagun Parakh, Andrew B. Lassman, Aidan Seow, Eddie Lau, Sze Ting Lee +10 more

The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.08.09.455687
N/A
0DataRank · unranked
2 citations

Thaís S. Sabedot, Indrani Datta, Luciano Garofano, Wies Vallentgoed, Frederick S. Varn +35 more

Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.05.03.442486
N/A
0DataRank · unranked
14 citations

Kevin C. Johnson, Taylor Wade, Tathiane M. Malta, Thaís S. Sabedot, Floris P Barthel +26 more

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

Neuro-Oncology(2022)10.1093/neuonc/noac173
N/A
0DataRank · unranked
153 citations

Stephanie L. Pugh, Tony J. C. Wang, Kenneth Aldape, Hui Gan, Matthias Preusser +27 more

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4064
N/A
0DataRank · unranked
44 citations

Nathan Standifer, Jörg Dietrich, Jennifer Clarke, Gavin P. Dunn, Michael Lim +21 more

Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

Nature Reviews Clinical Oncology(2023)10.1038/s41571-023-00756-z
N/A
0DataRank · unranked
93 citations

Rupert Bartsch, Émilie Le Rhun, Anna S. Berghoff, Priscilla K. Brastianos, Javier Cortés +8 more

The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen

Cancer Research(2023)10.1158/0008-5472.can-23-2093
N/A
0DataRank · unranked
57 citations

Thaís S. Sabedot, Natalia S. Morosini, Indrani Datta, Luciano Garofano, Wies Vallentgoed +67 more

Data from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6532395
Top 100%
0DataRank
Top 100%0 citations

Nathan Standifer, Jörg Dietrich, Jennifer Clarke, Gavin P. Dunn, Michael Lim +21 more

Data from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6532395.v1
Top 100%
0DataRank
Top 100%0 citations

Nathan Standifer, Jörg Dietrich, Jennifer Clarke, Gavin P. Dunn, Michael Lim +21 more

Detection of EGFR and its Activity State in Plasma CD63-EVs from Glioblastoma Patients: Rapid Profiling using an Anion Exchange Membrane Sensor

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.10.16.562628
N/A
0DataRank · unranked
0 citations

Sonu Kumar, Jeffrey L. Franklin, James N. Higginbotham, Andrew M. Scott, Hui Gan +4 more

An anion exchange membrane sensor detects EGFR and its activity state in plasma CD63 extracellular vesicles from patients with glioblastoma

Communications Biology(2024)10.1038/s42003-024-06385-1
N/A
0DataRank · unranked
18 citations

Sonu Kumar, Jeffrey L. Franklin, James N. Higginbotham, Andrew M. Scott, Hui Gan +4 more